Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astellas Pharma ADR Representing 1 Ord Shs ALPMY

Healthcare
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.

Recent & Breaking News (PINL:ALPMY)

ASTAGRAF XL(TM) (tacrolimus extended-release capsules), Prophylaxis of Organ Rejection in Adult Kidney Transplant Recipients, Now Available from Astellas

PR Newswire August 22, 2013

Astellas Confirms Interim Analysis in PREVAIL Study of XTANDI will Occur within Calendar Year 2013

PR Newswire August 1, 2013

Astellas Helps Patients Identify with their "OAB Reality"

PR Newswire July 24, 2013

Astellas Announces FDA Approval of ASTAGRAF XL(TM) (tacrolimus extended-release capsules) for the Prophylaxis of Organ Rejection in Adult Kidney Transplant Recipients

PR Newswire July 19, 2013

Dr. Helen Fisher to Speak at Astellas Presents Executive Women's Day at the Constellation SENIOR PLAYERS Championship

PR Newswire June 25, 2013

FDA Approves Pediatric Indication for Astellas' MYCAMINE® (micafungin sodium) for Injection

PR Newswire June 24, 2013

Molly Fletcher to Speak at Astellas Presents Executive Women's Day at the AT&T National

PR Newswire June 24, 2013